{"id":"https://openalex.org/W45199982","doi":null,"title":"Clinical research of EGFR inhibitors and related dermatologic toxicities.","display_name":"Clinical research of EGFR inhibitors and related dermatologic toxicities.","publication_year":2007,"publication_date":"2007-10-01","ids":{"openalex":"https://openalex.org/W45199982","mag":"45199982","pmid":"https://pubmed.ncbi.nlm.nih.gov/18154213"},"language":"en","primary_location":{"id":"pmid:18154213","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18154213","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108481953","display_name":"Roman Perez-Soler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I129975664","display_name":"Albert Einstein College of Medicine","ror":"https://ror.org/05cf8a891","country_code":"US","type":"education","lineage":["https://openalex.org/I129975664","https://openalex.org/I4210112371"]},{"id":"https://openalex.org/I1335289525","display_name":"Montefiore Medical Center","ror":"https://ror.org/044ntvm43","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1335289525","https://openalex.org/I19772626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roman Perez-Soler","raw_affiliation_strings":["Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. rperezso@montefiore.org","Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. rperezso@montefiore.org","institution_ids":["https://openalex.org/I129975664","https://openalex.org/I1335289525"]},{"raw_affiliation_string":"Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA","institution_ids":["https://openalex.org/I129975664","https://openalex.org/I1335289525"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090645179","display_name":"Eric Van Cutsem","orcid":"https://orcid.org/0000-0002-6372-1230","observed_orcids":["https://orcid.org/0000-0002-6372-1230"]},"institutions":[{"id":"https://openalex.org/I19772626","display_name":"Yeshiva University","ror":"https://ror.org/045x93337","country_code":"US","type":"education","lineage":["https://openalex.org/I19772626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Van Cutsem","raw_affiliation_strings":["Yeshiva University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yeshiva University","institution_ids":["https://openalex.org/I19772626"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.2795,"has_fulltext":false,"cited_by_count":32,"citation_normalized_percentile":{"value":0.90049597,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"21","issue":"11 Suppl 5","first_page":"10","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9819999933242798},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.8899999856948853},{"id":"https://openalex.org/keywords/acneiform-rash","display_name":"acneiform rash","score":0.8370000123977661},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.7239999771118164},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7229999899864197},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.6579999923706055}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8216052055358887},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.79216468334198},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.7081260085105896},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.687673807144165},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5976959466934204},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5311967730522156},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.519681990146637},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44875630736351013},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39062249660491943},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38917967677116394},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2010883390903473}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:18154213","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18154213","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:45199982","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18154213","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8399999737739563,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W63759084","https://openalex.org/W1924476721","https://openalex.org/W1970476748","https://openalex.org/W1988442083","https://openalex.org/W2002273560","https://openalex.org/W2024036818","https://openalex.org/W2046882295","https://openalex.org/W2049484790","https://openalex.org/W2054870962","https://openalex.org/W2058992264","https://openalex.org/W2067376187","https://openalex.org/W2084696062","https://openalex.org/W2103134643","https://openalex.org/W2121306031","https://openalex.org/W2123413031","https://openalex.org/W2135836172","https://openalex.org/W2136861363","https://openalex.org/W2139819066","https://openalex.org/W2142564546","https://openalex.org/W2142661339","https://openalex.org/W2158863975","https://openalex.org/W2168377135","https://openalex.org/W2272178001","https://openalex.org/W2548089746"],"related_works":["https://openalex.org/W2024901588","https://openalex.org/W2031520822","https://openalex.org/W2409992098","https://openalex.org/W2029017642","https://openalex.org/W2074142082","https://openalex.org/W4361004245","https://openalex.org/W2990741412","https://openalex.org/W2318947035","https://openalex.org/W2314308389","https://openalex.org/W2514659306"],"abstract_inverted_index":{"An":[0],"acneiform-like":[1],"skin":[2,102,118,131,156],"toxicity":[3,103,119,132,157],"is":[4,23,105],"commonly":[5],"observed":[6,51],"in":[7,32,82,163],"patients":[8,84],"with":[9,13,52],"solid":[10],"tumors":[11],"treated":[12],"epidermal":[14,26],"growth":[15,27],"factor":[16,28],"receptor":[17,29],"inhibitors":[18],"(EGFRIs).":[19],"This":[20],"symptomatic":[21],"rash":[22,45,63],"related":[24],"to":[25,87,94,112],"(EGFR)":[30],"inhibition":[31,73],"the":[33,39,115,130,151,155],"skin.":[34],"A":[35],"positive":[36],"relation":[37],"between":[38],"presence":[40],"and":[41,46,74,77,135,140,161],"severity":[42],"of":[43,70,79,117,129,154],"treatment-related":[44],"survival":[47],"has":[48],"been":[49],"consistently":[50],"all":[53],"EGFRIs":[54],"approved":[55],"for":[56,124],"clinical":[57,75,125,145,165],"use.":[58],"These":[59],"findings":[60],"suggest":[61],"that":[62],"may":[64],"be":[65,159],"a":[66,121],"useful":[67],"surrogate":[68,122],"marker":[69,123],"successful":[71],"EGFR":[72],"benefit":[76,88],"therefore":[78],"possible":[80],"use":[81],"identifying":[83],"most":[85],"likely":[86],"from":[89],"therapy,":[90],"as":[91,93,120],"well":[92],"guide":[95],"dose":[96,100],"adjustments.":[97],"Increasing":[98],"drug":[99],"until":[101],"appears":[104],"being":[106],"studied.":[107],"Further":[108],"studies":[109],"are":[110,133],"needed":[111],"thoroughly":[113],"evaluate":[114],"value":[116],"benefit.":[126],"Current":[127],"treatments":[128,148],"empirical":[134],"oriented":[136],"toward":[137],"mitigating":[138],"symptoms":[139],"not":[141],"validated":[142],"by":[143],"well-controlled":[144,164],"trials.":[146,166],"Rational":[147],"based":[149],"on":[150],"biological":[152],"mechanisms":[153],"must":[158],"developed":[160],"tested":[162]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}